Biological medicines in the treatment of inflammatory bowel disease in childhood and adolescence

Abstract

Basic characteristics of inflammatory bowel disease and addressing the underlying conditions in children and adolescence have been presented. Main principles of the treatment, current strategies, classification and approved biologics (adalimumab, infliximab) including biosimilars, indication, proper choice of therapeutic algorithm, pre-screening, monitoring, particular contraindications and adverse-effects have been established.

Keywords

• infmammatory bowel disease
• Crohn´s disease
• ulcerative colitis
• infliximab
• adalimumab
• biosimilars
• childhood